India's Ebola Odds Fall to 12% After 11,000 Travelers Screened Clean

India's probability of reporting an Ebola case before January 1, 2027 sits at 12% on Polymarket and 11% on Kalshi, down from 27% just three days ago, after the government confirmed zero positive detections among nearly 11,000 screened travelers. That 16-percentage-point drop is one of the sharpest single-outcome moves in the broader market tracking which countries will report an Ebola case in 2026.

Prediction-market view

Live prices, venue by venue

Compare the latest YES price at each venue. Check market rules, liquidity, and fees before trading.

India

Consensus YES price across 2 venues

19%average

KalshiBest YES price10¢Polymarket43¢

Central African Republic

Consensus YES price across 1 venues

38%average

KalshiBest YES price40¢

Tanzania

Consensus YES price across 1 venues

16%average

KalshiBest YES price17¢

Zambia

Consensus YES price across 1 venues

11%average

KalshiBest YES price12¢

Current new-user offer · Kalshi

Get a $35 trading bonusCode PRED35

New users only. Eligibility restrictions and terms apply.

View current offer

---

India Screened 11,000 Travelers for Ebola in 2026, and Markets Have Taken Notice

The core data point driving this repricing is concrete. India's Union Health Minister J.P. Nadda told the Lok Sabha that 10,974 travelers had been screened under enhanced Ebola surveillance protocols since May 2026, with zero positive detections. That number is not a projection or a policy promise. It is a completed surveillance sample large enough for markets to treat as meaningful evidence.

The timing matters. India's Ministry of Health and Family Welfare issued a formal public health advisory on June 2, 2026, escalating vigilance while reporting zero domestic cases. That advisory came weeks after screening protocols were activated at major international airports, deploying thermal scanning, travel history questionnaires, and isolation protocols for arrivals from high-risk regions.

The exact trigger for the three-day, 16-percentage-point drop is not entirely clear from publicly available reporting. The screening data and advisory predate the move. Markets may be responding to a cumulative reassessment: the longer India sustains a clean record against an expanding outbreak, the more each additional day of zero cases compounds the evidence that the firewall works. Whether a specific institutional or data release event catalyzed the move in the last 72 hours, the direction is unambiguous.

---

How India's Screening Infrastructure Became a Market Signal

Understanding what "screening 11,000 travelers" actually means requires context. India invested heavily in airport-level biosurveillance after the 2014 West Africa Ebola outbreak, building a network of airport health officers coordinated through state health ministries. When the Congo outbreak began accelerating earlier this year, those systems were reactivated, not built from scratch.

The screening protocol operates in layers. Travelers arriving from flagged countries undergo thermal scanning at entry points. Those with elevated temperatures or relevant travel histories are routed into secondary screening, which can include rapid diagnostics and mandatory quarantine. The system's design is not novel, but its scale and consistency are what the market appears to be pricing. Nearly 11,000 processed travelers with a 0% detection rate is a statistical sample that shrinks the plausible base rate for an imported case.

India's prior experience also matters. The country successfully contained a Nipah virus outbreak in Kerala in 2018 and managed COVID-19 screening at airports before community transmission rendered it moot. The institutional muscle memory for airport-based disease interception is well established. Markets are not just rewarding the current data. They are rewarding the infrastructure that produced it.

---

Congo's Outbreak Just Crossed 6,000 Cases. Why Is India's Risk Falling?

This is where the market move becomes genuinely counterintuitive. The Congo outbreak is not shrinking. latimes.com, making it one of the largest Ebola outbreaks on record. The WHO's disease outbreak report confirms the virus remains active across multiple provinces, and vaccination campaigns for health workers are still in early stages.

Under a simple geographic exposure model, a worsening source outbreak should push India's probability higher, not lower. More cases in Congo means more infected travelers potentially boarding flights. India has direct and indirect air connections to Central and East Africa that remain open. The raw inputs to transmission risk have not improved.

Yet the market is making a more nuanced calculation. It appears to be weighting surveillance quality over geographic proximity. The argument is straightforward: if 11,000 travelers have been screened and none tested positive, the effective importation rate through India's screening regime is functionally near zero, regardless of how many cases exist at the source. Every week that passes without a detection strengthens the prior.

---

The Case Against Complacency: What Could Make This Market Wrong

The strongest counterargument to 12% is that screening regimes fail at the margins, and Ebola only needs one miss. Airport thermal scanning does not catch travelers who are infected but pre-symptomatic. Ebola's incubation period can extend to 21 days, meaning a traveler could clear screening at arrival and develop symptoms weeks later in a domestic setting.

India's screening also depends on accurate self-reporting of travel history. Travelers transiting through third countries may not flag Congo-origin exposure, creating gaps in the questionnaire-based filtering layer. If the Congo outbreak spills into a neighboring country with heavier direct air traffic to India, the assumptions underlying the current screening perimeter could shift rapidly.

There is also a question of sample bias. The 11,000 screened travelers represent a filtered population: those who traveled through flagged routes. The risk of an imported case may be concentrated in informal travel channels or circuitous routing that bypasses primary screening points entirely.

At 12%, the market is pricing roughly a one-in-eight chance that India reports a case before year-end. That is not zero. But it is a price that assumes India's screening regime will continue to perform at its current level for three more months, against an outbreak that shows few signs of decelerating. The period low of 8% suggests some traders have been even more aggressive in discounting India's risk. The current 12% may reflect a partial correction from that floor, with the market settling into a range that acknowledges residual tail risk without pricing in a likely breach.

The bottom line: markets are treating India's surveillance infrastructure as a structural barrier, not a temporary policy. Whether that confidence survives a 6,000-plus case outbreak through the end of 2026 depends on whether the screening system can sustain a clean record. Three months is a long time to hold at zero.